AIM Immunotech vs Genelux
AIM Immunotech is the larger business, with $88,000 of revenue in fiscal 2025 against $8,000 for Genelux (11.0 times as much). Genelux grew faster (0.0% against -48.2%). AIM Immunotech kept more of each dollar of sales as profit: a net margin of -15861.4% against -401812.5%.
| Latest fiscal year | AIM ImmunotechAIM, 2025 | GeneluxGNLX, 2025 |
|---|---|---|
| Revenue | $88,000 | $8,000 |
| Revenue growth | -48.2% | 0.0% |
| Net income | −$14.0m | −$32.1m |
| Operating margin | -13254.5% | -415175.0% |
| Net margin | -15861.4% | -401812.5% |
| Return on equity | — | -170.0% |
| Free cash flow | −$11.0m | −$26.4m |
| Cash | $3.0m | $5.3m |
| Total debt | $8.0m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 19 | 25 |
| Market value | $4.7m | $87.5m |
| Price vs our value range | — | — |
| Moat score | 5 (Weak) | — |
| Insider trades, 12 months | 6 buys, 0 sales | 0 buys, 25 sales |